According to CNN, the shares of leading vaccine manufacturers plummeted on Thursday after President-elect Donald Trump ...

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...

Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward dividend yield currently stands at just under ...